Consensus Vertex Pharmaceuticals Incorporated Sao Paulo

Stocks

VRTX34

BRVRTXBDR001

Pharmaceuticals

Market Closed - Sao Paulo 07:46:17 19/10/2026 pm IST			5-day change	1st Jan Change
79.36 ^BRL	-0.30%		+0.40%	+1.43%

21/10	Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee	CI
15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT

cb0931f.Jj8jQtjZhomqONAmq3h0fc_v4QStzHy5YZ81YG3tuto.E0dUB5u66t_5W4UT7y8TLpaXg37rqh3oCch8CFuLgr1-RnMjr6_1_9lXvw~528c613e56dc88b8bf233fc3f3d5667b

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
08/10	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
02/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
12/08	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
11/08	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
11/08	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
05/08	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
04/08	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
04/08	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
04/08	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
04/08	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
04/08	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
04/08	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
04/08	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
04/08	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
04/08	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
21/07	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
20/07	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
13/07	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
09/07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
08/07	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07/07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT

More recommendations

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
VERTEX PHARMACEUTICALS INCORPORATED	-	-	-	-
ELI LILLY AND COMPANY				+3.71%
JOHNSON & JOHNSON				+7.73%
ABBVIE INC.				-2.24%
ROCHE HOLDING AG				-1.52%
MERCK & CO., INC.				+6.92%
NOVARTIS AG				-2.21%
ASTRAZENECA PLC				+24.46%
AMGEN INC.				-10.02%
GILEAD SCIENCES, INC.				+2.33%
Average				+3.24%
Weighted average by Cap.				+3.43%